Thiotepa - Shorla Oncology
Alternative Names: SH-105; TEPYLUTELatest Information Update: 28 Jun 2024
At a glance
- Originator Shorla Pharma
- Developer Shorla Oncology
- Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Adenocarcinoma
- Clinical Phase Unknown Bladder cancer
- Preclinical Brain metastases